Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1111
Peer-review started: February 12, 2019
First decision: April 18, 2019
Revised: April 24, 2019
Accepted: May 1, 2019
Article in press: May 1, 2019
Published online: May 26, 2019
Processing time: 108 Days and 18.7 Hours
Nosocomial infections with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC) strains are great problem for intensive care units. ABC strains can develop resistance to all the antibiotics available. Carbapenem resistance is common and colistin resistance is rare in our country. Knowing the risk factors for colistin resistance is important since colistin seems to be the only remaining therapeutic option for the patients with pneumonia due to extensively drug resistant ABC for our country.
To investigate the comparison of clinical responses and outcomes between pneumonia patients with colistin-susceptible and -resistant Acinetobacter sp. Strains.
During the study period, 108 patients with pneumonia due to colistin-susceptible strains and 16 patients with colistin-resistant strains were included retrospectively. Continuous variables were compared with the Mann-Whitney U test, and categorical variables were compared using Pearson’s chi-square test or Fisher’s Exact chi-square test for two groups. A binary logistic regression model was developed to identify the potential independent factors associated with colistin resistance in patients with colistin-resistant strains.
High Acute Physiology and Chronic Health Evaluation II scores (OR = 1.9, 95%CI: 1.4-2.7; P < 0.001) and prior receipt of teicoplanin (OR = 8.1, 95%CI: 1.0-63.3; P = 0.045) were found to be independent risk factors for infection with colistin-resistant Acinetobacter sp. Different combinations of antibiotics including colistin, meropenem, ampicillin/sulbactam, amikacin and trimethoprim/sulfamethoxazole were used for the treatment of patients with colistin-resistant strains. Although the median duration of microbiological cure (P < 0.001) was longer in the colistin-resistant group, clinical (P = 0.703), laboratory (P = 0.277), radiological (P = 0.551), microbiological response (P = 1.000) and infection related mortality rates (P = 0.603) did not differ between the two groups. Among the patients with infections due to colistin-resistant strains, seven were treated with antibiotic combinations that included sulbactam. Clinical (6/7) and microbiological (5/7) response rates were quite high in these patients.
The optimal therapy regimen is unclear for colistin-resistant Acinetobacter sp. infections. Although combinations with sulbactam seems to be more effective in our study patients, data supporting the usefulness of combinations with sulbactam is very limited.
Core tip:Acinetobacter baumannii-calcoaceticus complex (ABC) may cause serious infections. As Acinetobacter species are resistant to many antimicrobials, treatment options for them are extremely limited. Knowing risk factors is important for colistin resistance since colistin seems to be the only remaining therapeutic option for the patients with pneumonia due to extensively drug resistant ABC. We aimed to investigate the risk factors for colistin resistance in ABC strains isolated from the patients with ventilator associated pneumonia (VAP). We also compared clinical response and the outcome between VAP patients due to colistin susceptible and resistant Acinetobacter sp. strains. Furthermore, different treatment combinations were evaluated.